Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment

BACKGROUND: It was shown that immunocompromised patients have significantly reduced immunologic responses to COVID-19 vaccines. The immunogenicity of COVID-19 vaccine/infection in patients with solid tumors is reduced. We evaluated the immunologic response to COVID-19 and/or the BNT162b2 mRNA COVID-...

Descripción completa

Detalles Bibliográficos
Autores principales: Grinshpun, A., Rottenberg, Y., Ben-Dov, I.Z., Djian, E., Wolf, D.G., Kadouri, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469519/
https://www.ncbi.nlm.nih.gov/pubmed/34634634
http://dx.doi.org/10.1016/j.esmoop.2021.100283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469519/
https://www.ncbi.nlm.nih.gov/pubmed/34634634
http://dx.doi.org/10.1016/j.esmoop.2021.100283

Ejemplares similares